Ligand Pharmaceuticals

LGND Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$199.59

-0.02% today

52W: $93.58 – $227.92

52W Low: $93.58 Position: 78.9% 52W High: $227.92

🔗 Compare Brokers

Key Metrics

P/E Ratio

32.51x

Price-to-Earnings

Forward P/E

20.17x

Forward Price/Earnings

P/S Ratio

14.85x

Price-to-Sales

EV/EBITDA

45.67x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$4B

Market Capitalization

Revenue Growth

39.4%

YoY Revenue Growth

Profit Margin

46.42%

Net profit margin

ROE

13.47%

Return on Equity

Beta

Market sensitivity

Short Interest

8.81%

% of float sold short

Avg. Volume

227,008

Average daily volume

Valuation Analysis

Signal

Overvalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

10 analysts

Avg. Price Target

$245.10

+22.8% upside

Target Range

$220.00 – $277.00

About the Company

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and childre

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 47 Exchange: NGM